The global antifungal drugs market size was estimated at USD 15.8 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.8% from 2024 to 2030. The growing prevalence of fungal infections such as aspergillosis and candidiasis is one of the key factors propelling the market. Fungal infections encompass both systemic and superficial infections including infections of the skin, eye, mouth, and vagina. Antifungal products with fungicidal activity are mostly used to treat a wide array of diseases, such as athlete's foot, ringworm, and fungal meningitis, caused by fungal agents. Mounting cases of hospital-acquired or nosocomial infections and infectious diseases are poised to propel the growth of the market during the forecast period.

Gather more insights about the market drivers, restrains and growth of the Antifungal Drugs Market

Fungal diseases are a public health problem as they can affect any individual. However, there is severe threat of fungal infections to people with weak immune responses such as patients with AIDS. There is a high possibility of development of opportunistic fungal infections in these patients. According to statistics published by the CDC, every year, nearly 152,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 112,000 deaths per year globally. Most of the deaths are reported in sub-Saharan Africa, as the prevalence of HIV/AIDS is more in these countries. This indicates a potential unmet need for highly potent antifungal drugs.

Increase in awareness levels is expected to improve the diagnosis rate of fungal infections, which, in turn, is projected to drive the adoption rate of the treatment drugs. In September 2022, Fungal Disease Awareness Week was celebrated by CDC to highlight the importance of antifungal treatments, reducing resistance to antifungal drugs, and recognizing fungal infections at an early stage to reduce mortality rate. These initiatives are being conducted by authorities to improve the level of awareness. Organizations such as Aspergillosis Trust are working toward increasing the awareness levels about aspergillosis while platforms such as aspergillosis.org have introduced World Aspergillosis Day and raised funds in alliance with Fungal Infection Trust for patients.

Recent Developments

• In December 2023, Astellas Pharma received FDA approval for Cresemba, an antifungal drug, to treat invasive aspergillosis (IA) and invasive mucormycosis (IM) in children.

• In November 2023, Basilea Pharmaceutica acquires rights to fosmanogepix, a broad-spectrum antifungal, through an agreement with Amplyx Pharmaceuticals. The transformative move strengthens Basilea's clinical antifungal pipeline, with plans for phase 3 studies.

• In October 2023, Basilea Pharmaceutica acquires GR-2397, a clinical-stage antifungal compound, from Gravitas Therapeutics. Rebranded as BAL2062, it targets invasive mold infections, completing a phase 1 study. Basilea plans preclinical profiling, targeting phase 2 by H1 2025. The upfront payment is USD 2 million.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global schizophrenia drugs market size was valued at USD 7.90 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. The increasing demand is due to the rising prevalence of schizophrenia and other related mental health disorders worldwide.

• The global artemisinin combination therapy market size was valued at USD 597.2 million in 2023 and is projected to grow at a CAGR of 8.2% from 2024 to 2030. It is attributed to the rising malaria in various regions. Malaria remains a significant public health challenge, with millions of cases reported annually.

Antifungal Drugs Market Segmentation

Grand View Research has segmented the global antifungal drugs market report based on drug class, indication, dosage form, distribution channel, and region:

Antifungal Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Others

Antifungal Drugs Indication Outlook (Revenue, USD Million, 2018 - 2030)
• Dermatophytosis
• Aspergillosis
• Candidiasis
• Others

Antifungal Drugs Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)
• Oral Drugs
• Ointments
• Powders
• Others

Antifungal Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacies
• Retails Pharmacies
• Others

Antifungal Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Denmark
o Norway
o Sweden
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o Saudi Arabia
o UAE
o South Africa
o Kuwait

Order a free sample PDF of the Antifungal Drugs Market Intelligence Study, published by Grand View Research.

Key Companies profiled:
• Novartis AG
• Pfizer, Inc.
• Bayer AG
• Sanofi
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Abbott
• Glenmark
• Enzon Pharmaceuticals, Inc.
• Astellas Pharma, Inc.

Key Antifungal Drugs Company Insights

• Pfizer, Inc. is engaged in discovery, development, and manufacture of pharmaceutical products. It has a portfolio of vaccines and medicines. The company operates through two business segments: Essential Health (EH) and Innovative Health (IH).

• Merck & Co., Inc. is a global healthcare company involved in development, discovery, manufacture, and commercialization of prescription, branded, & over-the-counter vaccines, pharmaceuticals, and consumer care products for human & animal healthcare markets

• Enzon Pharmaceuticals, Inc. and Astellas Pharma, Inc. are some of the emerging market participants in the antifungal drugs market.

• Astellas Pharma, Inc. is engaged in import/export, manufacture, and marketing of pharmaceuticals. The company has products in the following segments: oncology, neurology, urology, nephrology, immunology, and women's health treatments.